In a clinical trial, a novel drug called „Donanemab” has led to a slowing of cognitive decline in people with early Alzheimer's disease. This was announced by the manufacturer Eli Lilly, which is seeking approval for the drug in the United States and other countries.
„Donanemab“ is a so-called amyloid antibody and targets specific proteins that are deposited in the brain in the course of Alzheimer’s disease. A similar drug called „Lecanemab” is currently undergoing the regulatory process in the EU. In the US, „Lecanemab“ is already on the market. While conventional drugs only have a symptomatic effect without addressing the causes of Alzheimer's, the novel drugs address the roots of the disease.